Valuation: Beijing Bohui Innovation Biotechnology Group Co., Ltd.

Market Cap 3.84B 567M 497M 459M 422M 797M 54.68B 810M 5.49B 2.15B 26.75B 2.13B 2.08B 92.17B P/E 2024
506x
P/E 2025 -55.7x
Enterprise Value 4.84B 715M 627M 579M 533M 1.01B 68.96B 1.02B 6.93B 2.72B 33.74B 2.69B 2.63B 116B EV / Sales 2024
6.63x
EV / Sales 2025 7.43x
Free-Float
37.78%
Yield 2024 *
-
Yield 2025 -
06-25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Announces Changes to Its Board CI
04-27 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-24 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-23 Beijing Bohui Innovation Biotechnology Group Co., Ltd. announced that it expects to receive CNY 300 million in funding CI
01-14 Bohui Innovation Biotechnology Gets Clinical Trial Approval for Anti-Rabies Human Rabies MT
11-12 Bohui Innovation Biotechnology JV Gets Clinical Trial Approval for Hib Vaccine MT
25-10-29 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-08-27 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-06-02 Bohui Innovation Biotechnology Secures Approval for Virus Detection Kit MT
25-04-28 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-04-25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25-02-21 Beijing Bohui Innovation Biotechnology Group Subsidiary Gains Clinical Trial Approval for Flu Vaccine MT
24-10-29 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
1 day-0.21%
1 week+2.84%
Current month+12.44%
1 month+5.62%
3 months-16.52%
6 months-28.57%
Current year-25.04%
1 week 4.59
Extreme 4.59
5.04
1 month 4.06
Extreme 4.06
5.04
Current year 4.06
Extreme 4.06
8.17
1 year 4.06
Extreme 4.06
8.63
3 years 3.43
Extreme 3.43
8.63
5 years 3.43
Extreme 3.43
14.98
10 years 3.43
Extreme 3.43
23.8
Manager TitleAgeSince
Chief Executive Officer 56 2020-03-16
Director of Finance/CFO 42 2020-06-28
Corporate Officer/Principal 48 2020-03-16
Director TitleAgeSince
Chairman 58 2014-05-18
Director/Board Member 59 2020-06-28
Chairman 48 2022-05-31
Date Insider Type Main position Quantity % Market Cap.
11/2/21 Sell

Executive/Senior Manager

268,300 0.0364%
9/15/21 Sell

Executive/Senior Manager

50,000 0.0068%
1/26/21 Buy

Chairman

29,000 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-0.21%+2.84%-24.80%-11.65% 568M
-0.67%+1.37%+23.89%-7.04% 68.85B
-0.54%+1.02%+36.12%+189.96% 52.13B
-3.65%+34.50%+34.50%+34.50% 43.46B
-0.67%-0.98%-52.31%-54.41% 41.24B
-2.93%-4.34%+59.97%-27.21% 30.41B
-3.77%-11.22%+90.31%-52.32% 24.53B
-1.36%+1.24%+70.42%+80.67% 23.42B
0.00%+2.22%+3.84%+180.64% 19.75B
+0.26%+0.39%+70.47%+126.52% 16.57B
Average -1.40%-2.18%+31.24%+45.97% 32.09B
Weighted average by Cap. -1.50%-1.42%+30.50%+43.96%

Financials

2024 2025
Net sales 852M 126M 110M 102M 93.72M 177M 12.13B 180M 1.22B 478M 5.93B 472M 462M 20.45B 825M 122M 107M 98.66M 90.74M 171M 11.74B 174M 1.18B 462M 5.75B 457M 447M 19.79B
Net income 9.25M 1.37M 1.2M 1.11M 1.02M 1.92M 132M 1.95M 13.23M 5.19M 64.42M 5.13M 5.02M 222M -91.92M -13.57M -11.9M -11M -10.12M -19.09M -1.31B -19.39M -132M -51.55M -640M -50.97M -49.86M -2.21B
Net Debt 974M 144M 126M 117M 107M 202M 13.87B 205M 1.39B 546M 6.79B 540M 528M 23.38B 1B 148M 130M 120M 110M 208M 14.29B 212M 1.44B 563M 6.99B 556M 544M 24.09B
Logo Beijing Bohui Innovation Biotechnology Group Co., Ltd.
Beijing Bohui Innovation Biotechnology Group Co Ltd, formerly Beijing Bohui Innovation Biotechnology Co Ltd is a China-based company mainly engaged in testing and biological products. The testing business products are divided into testing instruments and testing reagents, including human papillomavirus (HPV) testing products, trace element testing products, mass spectrometry related testing products, and others. The biological products mainly cover three categories: albumin, immunoglobulin and human coagulation factors, including human serum albumin, human immunoglobulin, intravenous human immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, and others. The Company mainly operates its business in the domestic market.
Employees
2,170
Date Price Change Volume
26-07-20 CN¥4.700 -0.21% 11,712,000
26-07-17 CN¥4.710 -5.80% 16,939,905
26-07-16 CN¥5.000 +2.88% 16,320,795
26-07-15 CN¥4.860 +0.62% 18,066,891
26-07-14 CN¥4.830 +5.69% 26,571,805
  1. Stock Market
  2. Stocks
  3. 300318 Stock